Acumen Pharmaceuticals (ABOS) Stock: Buy, Sell, or Hold?
ABOS - Acumen Pharmaceuticals, Inc. Common Stock
$1.98
-0.08 (-4.13%)
▼
5d:
+16.86%
30d:
-11.63%
90d:
-10.23%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 26, 2026
2d
Get Alerted When ABOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABOS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ABOS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ABOS is currently trading at $1.98, which is considered slightly low relative to its 30-day fair value range of $1.87 to $2.51.
Technical Outlook: Technically, ABOS is showing sideways momentum. Immediate support is located at $1.62, while resistance sits at $2.14. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: ABOS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.60 (+268.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABOS is showing sideways momentum. Immediate support is located at $1.62, while resistance sits at $2.14. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: ABOS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.60 (+268.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.87 -
$2.51
Company Quality Score
60/100
(BUY)
Options IV Signal
57th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
85.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 57th percentile)
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 268.9% below Wall St target ($7.60)
- BULLISH: Bottoming setup score 73/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.87 -
$2.51
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.60
(30.5%)
Support & Resistance Levels
Support Level
$1.62
Resistance Level
$2.14
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.44
Wall Street Target
$7.60
(+268.9%)
Share & Embed Analysis
Last updated: October 23, 2026 2:06 PM ET
Data refreshes hourly during market hours. Next update: 3:06 PM
Data refreshes hourly during market hours. Next update: 3:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 63 BUY |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 63 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
